Codon-Optimized Dystrophin Gene Therapy for Muscular Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for muscular dystrophies, such as Duchenne muscular dystrophy, are limited in their applicability, often targeting specific mutations and resulting in truncated, semi-functional dystrophin proteins, which are not universally effective and do not restore the full-length dystrophin protein, thereby not addressing the needs of a broader patient population.
Innovation Solution
A codon-optimized full-length human dystrophin cDNA sequence is developed, which increases protein expression by up to 22-fold compared to the native sequence, allowing for the production of a functional dystrophin protein that can be used in vectors for therapeutic delivery to treat muscular dystrophies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current gene therapy approaches targeting specific mutations are used, then treatment can be provided to certain patient cohorts, but the therapeutic applicability is limited and only a small proportion of patients can benefit
Solution Approach 1:
The patent develops a universal gene therapy approach using AAV vectors that can deliver functional dystrophin to patients with different DMD mutations. Instead of creating multiple mutation-specific therapies, a single platform can be applied across diverse patient cohorts, making the treatment universally applicable while covering a large proportion of patients
2Ease of manufacture
If truncated microdystrophin is used in AAV vectors, then gene delivery is achieved, but key domains of the full-length protein are removed resulting in sub-optimal function
Solution Approach 1:
The patent optimizes the dystrophin coding sequence through codon optimization to enhance protein expression levels from AAV vectors. This parameter change in the nucleotide sequence allows sufficient expression of full-length dystrophin from the limited AAV cargo capacity, achieving both feasible gene delivery and reliable full-length protein function
3Reliability
If the native wild-type human dystrophin gene sequence is used, then the correct dystrophin protein is encoded, but protein expression levels are insufficient for effective therapy
Solution Approach 1:
The patent applies codon optimization to the dystrophin coding sequence, changing the nucleotide parameters while maintaining the amino acid sequence. This optimization of codon usage increases translational efficiency and protein expression levels, achieving both correct dystrophin protein and sufficient productivity for effective therapy
Data Source
AI summary
There is described a nucleic acid molecule comprising a nucleotide sequence encoding a functional dystrophin protein. Also described is a vector, a host cell and a pharmaceutical composition comprising the nucleic acid molecule; use of the nucleic acid molecule in therapy, such as in the treatment of a muscular dystrophy; and a method of treating muscular dystrophy, the method comprising administering a therapeutically effective amount of the nucleic acid molecule to a patient suffering from a muscular dystrophy.